Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Trial Profile

The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.
    • 10 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
    • 02 Nov 2018 Planned initiation date changed from 1 Aug 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top